Literature DB >> 8597273

Prevalence of retinal hemorrhages in infants after extracorporeal membrane oxygenation.

J S Pollack1, L Tychsen.   

Abstract

PURPOSE: To determine the prevalence of vision-threatening retinal hemorrhages in infants after venoarterial extracorporeal membrane oxygenation, and possible correlation between retinal hemorrhages and brain hemorrhages, thrombocytopenia, carotid reanastomosis, or death after extracorporeal membrane oxygenation.
METHODS: We reviewed the findings of dilated ophthalmoscopic examinations performed on 37 children an average of 16 days after extracorporeal membrane oxygenation (35 neonates and two 1-year-old children).
RESULTS: Five (13%) of the 37 children examined had small (< or = 1 disk diameter) intraretinal hemorrhages. Presence or absence of retinal hemorrhages did not correlate with presence of cerebral hemorrhage, mean platelet count during extracorporeal membrane oxygenation, a history of reanastomosis of the carotid artery, or subsequent death.
CONCLUSION: Retinal hemorrhages observed after extracorporeal membrane oxygenation are not necessarily caused by extracorporeal membrane oxygenation; some hemorrhages may be benign and related to parturition. Children who undergo venoarterial extracorporeal membrane oxygenation are at low risk for vision-threatening retinal hemorrhage.

Entities:  

Mesh:

Year:  1996        PMID: 8597273     DOI: 10.1016/s0002-9394(14)70278-8

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  3 in total

1.  A 12-year ophthalmologic experience with the shaken baby syndrome at a regional children's hospital.

Authors:  J D Kivlin
Journal:  Trans Am Ophthalmol Soc       Date:  1999

Review 2.  Review: The Development of Risk Factors and Cytokines in Retinal Vein Occlusion.

Authors:  Yi Tang; Yan Cheng; Shuo Wang; Yongjie Wang; Pengjia Liu; Hong Wu
Journal:  Front Med (Lausanne)       Date:  2022-06-15

3.  Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study.

Authors:  Qinrui Hu; Yujing Bai; Xiaoli Chen; Lvzhen Huang; Yi Chen; Xiaoxin Li
Journal:  J Ophthalmol       Date:  2017-04-09       Impact factor: 1.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.